- Shah, Neil Pravin;
- Ciceri, P;
- Müller, S;
- O'Mahony, A;
- Fedorov, O;
- Filippakopoulos, P;
- Hunt, JP;
- Lasater, EA;
- Pallares, G;
- Picaud, S;
- Wells, C
Concomitant inhibition of multiple cancer-driving kinases is an established strategy to improve the durability of clinical responses to targeted therapies. The difficulty of discovering kinase inhibitors with an appropriate multitarget profile has, however
